{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T22:40:33Z","timestamp":1787870433783,"version":"build-2784847793"},"reference-count":32,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"5","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,7]]},"abstract":"<jats:sec>\n            <jats:title>Background:<\/jats:title>\n            <jats:p>The standard-risk hepatoblastoma has a good prognosis in children; however, refractory or relapsed (R\/R) hepatoblastoma has a poor prognosis and high mortality rate. This study aimed to demonstrate the efficacy of high-dose chemotherapy and autologous hematopoietic stem cell transplantation (HSCT) rescue in pediatric patients with R\/R hepatoblastoma.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods:<\/jats:title>\n            <jats:p>We retrospectively analyzed 6 pediatric patients with R\/R hepatoblastoma who underwent autologous HSCT. The MEC conditioning regimen was used for all patients, comprising melphalan 140\u00a0mg\/m<jats:sup>2<\/jats:sup>\/day intravenously (IV) on day 7 and 70\u00a0mg\/m<jats:sup>2<\/jats:sup> on day 6, etoposide 200\u00a0mg\/m<jats:sup>2<\/jats:sup> IV on days 5 to 8, and carboplatin 400\u00a0mg\/m<jats:sup>2<\/jats:sup> IV on days 5 to 8. One patient received a TopoThioCarbo regimen, comprising topotecan 2\u00a0mg\/m<jats:sup>2<\/jats:sup>\/day IV on days 4 to 8, thiotepa 300\u00a0mg\/m<jats:sup>2<\/jats:sup>\/day IV on days 6 to 8, and carboplatin 500\u00a0mg\/m<jats:sup>2<\/jats:sup>\/day IV on days 3 to 5, as the conditioning regimen for the first transplantation. This was followed by salvage chemotherapy for relapse, and the second transplantation was performed using MEC as the conditioning regimen.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results:<\/jats:title>\n            <jats:p>We report the retrospective results of 6 patients with a median age of 1.8 (range 0.4 to 10.2) years who had R\/R hepatoblastoma and underwent autologous HSCT. The median follow-up period was 58 (range 28 to 113) months after diagnosis. The median stage at diagnosis was 2.0 (range 2 to 4). Two patients had lung metastases during diagnosis. The median initial alpha-fetoprotein level was 292,888 (range 28,831 to 2,406,942) ng\/mL, and the median number of chemotherapy lines before autologous HSCT was 3.5 (range 2 to 7). The disease status before HSCT was complete remission (CR) for all patients. The engraftment rate was 100%. No treatment-related mortality was reported. The 3-year event-free survival and overall survival rates were 83.3% and 100%, respectively. One patient relapsed after the second HSCT and achieved CR after salvage chemotherapy.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusion:<\/jats:title>\n            <jats:p>This study suggests autologous HSCT as an effective treatment in pediatric patients with R\/R hepatoblastoma. Nevertheless, future large-scale prospective studies are warranted.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/mph.0000000000002888","type":"journal-article","created":{"date-parts":[[2024,6,3]],"date-time":"2024-06-03T20:00:10Z","timestamp":1717444810000},"page":"e265-e271","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":2,"title":["Successful Treatment of Refractory or Relapsed Hepatoblastoma With Autologous Hematopoietic Stem Cell Transplantation in Children"],"prefix":"10.1097","volume":"46","author":[{"given":"Bo Kyung","family":"Kim","sequence":"first","affiliation":[{"name":"Department of Pediatrics, Seoul National University College of Medicine"},{"name":"Seoul National University Cancer Research Institute, Seoul, Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jung Yoon","family":"Choi","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Seoul National University College of Medicine"},{"name":"Seoul National University Cancer Research Institute, Seoul, Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyung Taek","family":"Hong","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Seoul National University College of Medicine"},{"name":"Seoul National University Cancer Research Institute, Seoul, Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hyun Jin","family":"Park","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Seoul National University College of Medicine"},{"name":"Seoul National University Cancer Research Institute, Seoul, Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hyoung Jin","family":"Kang","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Seoul National University College of Medicine"},{"name":"Seoul National University Cancer Research Institute, Seoul, Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2024,5,31]]},"reference":[{"key":"R1-20250804","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1111\/j.1365-3016.1990.tb00651.x","article-title":"Malignant hepatic tumours in children: incidence, clinical features and aetiology","volume":"4","author":"Mann","year":"1990","journal-title":"Paediatric and perinatal epidemiology"},{"key":"R2-20250804","doi-asserted-by":"crossref","first-page":"2665","DOI":"10.1200\/JCO.2000.18.14.2665","article-title":"Randomized comparison of cisplatin\/vincristine\/fluorouracil and cisplatin\/continuous infusion doxorubicin for treatment of pediatric hepatoblastoma: A report from the Children\u2019s Cancer Group and the Pediatric Oncology Group","volume":"18","author":"Ortega","year":"2000","journal-title":"Journal of clinical oncology : official journal of the American Society of Clinical Oncology"},{"key":"R3-20250804","doi-asserted-by":"crossref","first-page":"3819","DOI":"10.1200\/JCO.2000.18.22.3819","article-title":"Cisplatin, doxorubicin, and delayed surgery for childhood hepatoblastoma: a successful approach--results of the first prospective study of the International Society of Pediatric Oncology","volume":"18","author":"Pritchard","year":"2000","journal-title":"Journal of clinical oncology: official journal of the American Society of Clinical Oncology"},{"key":"R4-20250804","doi-asserted-by":"crossref","first-page":"1662","DOI":"10.1056\/NEJMoa0810613","article-title":"Cisplatin versus cisplatin plus doxorubicin for standard-risk hepatoblastoma","volume":"361","author":"Perilongo","year":"2009","journal-title":"The New England journal of medicine"},{"key":"R5-20250804","doi-asserted-by":"crossref","first-page":"2584","DOI":"10.1200\/JCO.2009.22.4857","article-title":"Successful treatment of childhood high-risk hepatoblastoma with dose-intensive multiagent chemotherapy and surgery: final results of the SIOPEL-3HR study","volume":"28","author":"Zs\u00edros","year":"2010","journal-title":"Journal of clinical oncology: official journal of the American Society of Clinical Oncology"},{"key":"R6-20250804","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1016\/j.jpedsurg.2015.10.053","article-title":"Relapsed hepatoblastoma confined to the lung is effectively treated with pulmonary metastasectomy","volume":"51","author":"Shi","year":"2016","journal-title":"Journal of pediatric surgery"},{"key":"R7-20250804","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1007\/s00383-002-0906-0","article-title":"Analysis of treatment outcome for children with recurrent or metastatic hepatoblastoma","volume":"19","author":"Matsunaga","year":"2003","journal-title":"Pediatric Surgery International"},{"key":"R8-20250804","doi-asserted-by":"crossref","first-page":"2379","DOI":"10.1200\/JCO.2006.09.7204","article-title":"Redefining the role of doxorubicin for the treatment of children with hepatoblastoma","volume":"26","author":"Malogolowkin","year":"2008","journal-title":"Journal of clinical oncology: official journal of the American Society of Clinical Oncology"},{"key":"R9-20250804","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1016\/j.ejca.2012.10.003","article-title":"Relapses in hepatoblastoma patients: clinical characteristics and outcome--experience of the International Childhood Liver Tumour Strategy Group (SIOPEL)","volume":"49","author":"Semeraro","year":"2013","journal-title":"European journal of cancer (Oxford, England: 1990)"},{"key":"R10-20250804","doi-asserted-by":"crossref","first-page":"105","DOI":"10.2298\/ACI0902105K","article-title":"Successful treatment of second hepatoblastoma relapse--case report","volume":"56","author":"Krstovski","year":"2009","journal-title":"Acta chirurgica Iugoslavica"},{"key":"R11-20250804","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1111\/j.1399-3046.2006.00517.x","article-title":"Response of heavily treated and relapsed hepatoblastoma in the transplanted liver to single-agent therapy with irinotecan","volume":"10","author":"Ijichi","year":"2006","journal-title":"Pediatric transplantation"},{"key":"R12-20250804","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1002\/mpo.10300","article-title":"Dramatic response of multiply relapsed hepatoblastoma to irinotecan (CPT-11)","volume":"41","author":"Palmer","year":"2003","journal-title":"Medical and pediatric oncology"},{"key":"R13-20250804","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1002\/pbc.20227","article-title":"Ifosfamide, carboplatin, and etoposide (ICE) reinduction chemotherapy in a large cohort of children and adolescents with recurrent\/refractory sarcoma: the Children's Cancer Group (CCG) experience","volume":"44","author":"Van Winkle","year":"2005","journal-title":"Pediatr Blood Cancer"},{"key":"R14-20250804","doi-asserted-by":"crossref","first-page":"e295","DOI":"10.1097\/MPH.0b013e3182441588","article-title":"Docetaxel in the treatment of children with refractory or relapsed hepatoblastoma","volume":"34","author":"George","year":"2012","journal-title":"J Pediatr Hematol Oncol"},{"key":"R15-20250804","doi-asserted-by":"crossref","first-page":"3456","DOI":"10.1016\/j.ejca.2012.06.023","article-title":"Efficacy of irinotecan single drug treatment in children with refractory or recurrent hepatoblastoma-a phase II trial of the childhood liver tumour strategy group (SIOPEL)","volume":"48","author":"Zs\u00edros","year":"2012","journal-title":"Eur J Cancer"},{"key":"R16-20250804","first-page":"2966","article-title":"Etoposide, ifosfamide, and cisplatin therapy for refractory childhood solid tumors","volume":"75","author":"van Hoff","year":"1995","journal-title":"Response and toxicity Cancer"},{"key":"R17-20250804","doi-asserted-by":"crossref","first-page":"18","DOI":"10.3109\/08880018.2014.909913","article-title":"Vincristine and irinotecan in children with relapsed hepatoblastoma: a single-institution experience","volume":"32","author":"Zhang","year":"2015","journal-title":"Pediatr Hematol Oncol"},{"key":"R18-20250804","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1002\/1097-0142(19820901)50:5<821::AID-CNCR2820500502>3.0.CO;2-K","article-title":"Combination chemotherapy (vincristine, adriamycin, cyclophosphamide, and 5-fluorouracil) in the treatment of children with malignant hepatoma","volume":"50","author":"Evans","year":"1982","journal-title":"Cancer"},{"key":"R19-20250804","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1002\/mpo.2950190310","article-title":"Effectiveness and toxicity of cisplatin and doxorubicin (PLADO) in childhood hepatoblastoma and hepatocellular carcinoma: a SIOP pilot study","volume":"19","author":"Ninane","year":"1991","journal-title":"Medical and pediatric oncology"},{"key":"R20-20250804","doi-asserted-by":"crossref","first-page":"2167","DOI":"10.1200\/JCO.1991.9.12.2167","article-title":"Effective treatment of unresectable or metastatic hepatoblastoma with cisplatin and continuous infusion doxorubicin chemotherapy: a report from the Childrens Cancer Study Group","volume":"9","author":"Ortega","year":"1991","journal-title":"Journal of clinical oncology: official journal of the American Society of Clinical Oncology"},{"key":"R21-20250804","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1200\/JCO.1993.11.1.96","article-title":"Cisplatin, vincristine, and fluorouracil therapy for hepatoblastoma: a Pediatric Oncology Group study","volume":"11","author":"Douglass","year":"1993","journal-title":"Journal of clinical oncology : official journal of the American Society of Clinical Oncology"},{"key":"R22-20250804","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1002\/1097-0142(19820915)50:6<1061::AID-CNCR2820500607>3.0.CO;2-Q","article-title":"Preoperative chemotherapy for unresectable primary hepatic malignancies in children","volume":"50","author":"Weinblatt","year":"1982","journal-title":"Cancer"},{"key":"R23-20250804","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1016\/j.pedneo.2021.03.018","article-title":"A retrospective study of clinical features and outcome in patients with refractory or recurrent hepatoblastoma: A single institution experience","volume":"62","author":"Hou","year":"2021","journal-title":"Pediatrics & Neonatology"},{"key":"R24-20250804","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1111\/ped.14134","article-title":"Novel treatment of refractory\/recurrent pulmonary hepatoblastoma","volume":"62","author":"Zhang","year":"2020","journal-title":"Pediatrics international : official journal of the Japan Pediatric Society"},{"key":"R25-20250804","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1002\/pbc.20404","article-title":"Allogeneic graft-versus-hepatoblastoma effect","volume":"46","author":"Inaba","year":"2006","journal-title":"Pediatric Blood & Cancer"},{"key":"R26-20250804","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1038\/sj.bmt.1701283","article-title":"Double-conditioning regimens consisting of thiotepa, melphalan and busulfan with stem cell rescue for the treatment of pediatric solid tumors","volume":"22","author":"Hara","year":"1998","journal-title":"Bone Marrow Transplant"},{"key":"R27-20250804","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1097\/00043426-200212000-00014","article-title":"Novel therapeutic approaches in the treatment of children with hepatoblastoma","volume":"24","author":"Katzenstein","year":"2002","journal-title":"J Pediatr Hematol Oncol"},{"key":"R28-20250804","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1046\/j.1442-200X.2002.01549.x","article-title":"High-dose chemotherapy in children with metastatic hepatoblastoma","volume":"44","author":"Nishimura","year":"2002","journal-title":"Pediatr Int"},{"key":"R29-20250804","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1111\/j.1399-3046.2008.00948.x","article-title":"Successful autologous peripheral blood stem cell transplantation with a double-conditioning regimen for recurrent hepatoblastoma after liver transplantation","volume":"13","author":"Niwa","year":"2009","journal-title":"Pediatr Transplant"},{"key":"R30-20250804","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1016\/j.pedneo.2021.03.018","article-title":"A retrospective study of clinical features and outcome in patients with refractory or recurrent hepatoblastoma: A single institution experience","volume":"62","author":"Hou","year":"2021","journal-title":"Pediatrics & Neonatology"},{"key":"R31-20250804","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1002\/pbc.24218","article-title":"Relapsed hepatoblastoma","volume":"59","author":"Trobaugh-Lotrario","year":"2012","journal-title":"Pediatric blood & cancer"},{"key":"R32-20250804","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.3892\/ol.2015.3272","article-title":"High-dose chemotherapy combined with autologous peripheral blood stem cell transplantation in children with advanced malignant solid tumors: A retrospective analysis of 38 cases","volume":"10","author":"Zhang","year":"2015","journal-title":"Oncology letters"}],"container-title":["Journal of Pediatric Hematology\/Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MPH.0000000000002888","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,4]],"date-time":"2025-08-04T20:06:39Z","timestamp":1754337999000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MPH.0000000000002888"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,31]]},"references-count":32,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2024]]}},"URL":"https:\/\/doi.org\/10.1097\/mph.0000000000002888","relation":{},"ISSN":["1077-4114"],"issn-type":[{"value":"1077-4114","type":"print"}],"subject":[],"published":{"date-parts":[[2024,5,31]]},"assertion":[{"value":"2023-10-25","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-04-17","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}